Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease.

Wimo A, Winblad B, Stöffler A, Wirth Y, Möbius HJ.

Pharmacoeconomics. 2003;21(5):327-40.

PMID:
12627986
2.

Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.

Plosker GL, Lyseng-Williamson KA.

Pharmacoeconomics. 2005;23(2):193-206. Review.

PMID:
15748093
3.

Memantine for dementia.

Areosa SA, Sherriff F.

Cochrane Database Syst Rev. 2003;(3):CD003154. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD003154.

PMID:
12917950
4.

Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.

Bullock R.

Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):23-9. Review.

PMID:
16493232
5.

Memantine for dementia.

Areosa SA, Sherriff F.

Cochrane Database Syst Rev. 2003;(1):CD003154. Review. Update in: Cochrane Database Syst Rev. 2003;(3):CD003154.

PMID:
12535459
6.

Memantine for dementia.

Areosa SA, Sherriff F, McShane R.

Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003154. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003154.

PMID:
15846650
7.

Memantine for dementia.

Areosa SA, Sherriff F, McShane R.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003154. Review. Update in: Cochrane Database Syst Rev. 2006;(2):CD003154.

PMID:
16034889
8.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
9.

Memantine for dementia.

Areosa Sastre A, McShane R, Sherriff F.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003154. Review. Update in: Cochrane Database Syst Rev. 2005;(2):CD003154.

PMID:
15495043
10.

Memantine for dementia.

McShane R, Areosa Sastre A, Minakaran N.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003154. Review.

PMID:
16625572
11.

Donepezil for dementia due to Alzheimer's disease.

Birks J, Harvey RJ.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001190. Review.

PMID:
16437430
12.

Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses using realistic definitions of response.

Wilkinson D, Wirth Y, Goebel C.

Dement Geriatr Cogn Disord. 2014;37(1-2):71-85. doi: 10.1159/000353801. Epub 2013 Oct 3. Review.

PMID:
24107324
13.

A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease.

Kirby J, Green C, Loveman E, Clegg A, Picot J, Takeda A, Payne E.

Drugs Aging. 2006;23(3):227-40. Review.

PMID:
16608378
14.

Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.

Lamb HM, Goa KL.

Pharmacoeconomics. 2001;19(3):303-18. Review.

PMID:
11303418
15.

The costs of Alzheimer's disease and the value of effective therapies.

Stefanacci RG.

Am J Manag Care. 2011 Nov;17 Suppl 13:S356-62. Review.

16.

Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer's disease?

Doggrell S.

Expert Opin Pharmacother. 2003 Oct;4(10):1857-60. Review.

PMID:
14521495
17.

Memantine.

Jarvis B, Figgitt DP.

Drugs Aging. 2003;20(6):465-76; discussion 477-8. Review.

PMID:
12710865
18.

Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU.

Lyseng-Williamson KA, McKeage K.

Drugs Aging. 2013 Jan;30(1):51-8. doi: 10.1007/s40266-012-0041-0. Review.

PMID:
23229767
19.

Economic considerations in the management of Alzheimer's disease.

Zhu CW, Sano M.

Clin Interv Aging. 2006;1(2):143-54. Review.

20.

Alzheimer's disease costs: what we know and what we should take into account.

Colucci L, Bosco M, Fasanaro AM, Gaeta GL, Ricci G, Amenta F.

J Alzheimers Dis. 2014;42(4):1311-24. doi: 10.3233/JAD-131556. Review.

PMID:
25024334

Supplemental Content

Support Center